Роль менопаузальной гормональной терапии в профилактике сахарного диабета 2 типа у женщин в постменопаузе


DOI: https://dx.doi.org/10.18565/pharmateca.2022.4.26-32

С.С. Апетов, В.В. Апетова

ООО «Центр эндокринного здоровья», Челябинск, Россия
Заболеваемость сахарным диабетом типа 2 (СД2) постоянно растет во всем мире, становясь значимой проблемой для здоровья из-за связанного с этим заболеванием более высокого риска сердечно-сосудистых осложнений. Лучшее понимание патофизиологии СД2 у женщин в постменопаузе может изменить профилактические стратегии и улучшить результаты лечения. Роль менопаузальной гормональной терапии в профилактике СД2 до конца не изучена, главным образом ввиду отсутствия достаточных результатов рандомизированных клинических исследований, однако имеющиеся данные свидетельствуют о значительном снижении риска впервые выявленного СД2 у получающих эту терапию.

Литература


1. The IDF Diabetes Atlas 10th edition, 2021. URL: https://diabetesatlas.org/atlas/tenth-edition/.


2. Dedov I., Shestakova M., Benedetti M.M., et al. Prevalence of type 2 diabetes mellitus (T2DM) in the adult Russian population (NATION study). Diabetes Res Clin Pract. 2016;115:90-5. Doi: 10.1016/j.diabres.2016.02.010.


3. Barbiellini Amidei C., Fayosse A., Dumurgier J., et al. Association Between Age at Diabetes Onset and Subsequent Risk of Dementia. JAMA. 2021;325(16):1640-49. Doi: 10.1001/ jama.2021.4001.


4. URL: https://www.cdc.gov/diabetes/pdfs/data/ statistics/national-diabetes-statistics-report.pdf


5. Narayan K.M., Boyle J.P., Thompson T.J., et al. Lifetime risk for diabetes mellitus in the United States. JAMA. 2003;290(14):1884-90. Doi: 10.1001/jama.290.14.1884.


6. Sattar N., Rawshani A., Franzen S., et al. Age at Diagnosis of Type 2 Diabetes Mellitus and Associations With Cardiovascular and Mortality Risks. Circulation. 2019;139(19):2228-37. Doi: 10.1161/CIRCULATIONAHA.118.037885.


7. Elks C.E., Ong K.K., Scott R.A., et al. Age at menarche and type 2 diabetes risk: the EPIC-InterAct study. Diabetes Care. 2013;36(11):3526-34. Doi:10.2337/dc13-0446.


8. Anagnostis P., Paparodis R.D., Bosdou J.K., et al. Risk of type 2 diabetes mellitus in polycystic ovary syndrome is associated with obesity: a meta-analysis of observational studies. Endocrine. 2021;74(2):245-53. Doi: 10.1007/s12020- 021-02801-2.


9. Dennison R.A., Chen E.S., Green M.E., et al. The absolute and relative risk of type 2 diabetes after gestational diabetes: A systematic review and meta-analysis of 129 studies. Diabetes Res Clin Pract. 2021;171:108625. Doi: 10.1016/j. diabres.2020.108625.


10. Li P., Shan Z., Zhou L., et al. MECHANISMS IN ENDOCRINOLOGY: Parity and risk of type 2 diabetes: a systematic review and doseresponse meta-analysis. Eur J Endocrinol. 2016;175(5):R231-45. Doi: 10.1530/EJE-16- 0321.


11. Tobias D.K., Gaskins A.J., Missmer S.A., et al. History of infertility and risk of type 2 diabetes mellitus: a prospective cohort study. Diabetologia. 2015;58(4):707-15. Doi: 10.1007/s00125- 015-3493-z.


12. Ye F., Wen J., Yang A., et al. The Influence of Hormone Therapy on secondary diabetes mellitus in Breast Cancer: A Meta-analysis. Clin Breast Cancer. 2022 Jan;22(1):e48-e58. Doi: 10.1016/j.clbc.2021.06.014.


13. Stepaniak U., Szafraniec K., Kubinova R., et al. Age at natural menopause in three central and eastern European urban populations: the HAPIEE study. Maturitas. 2013;75(1):87-93. Doi:10.1016/j. maturitas.2013.02.008.


14. Paschou S.A., Anagnostis P., Pavlou D.I., et al. Diabetes in Menopause: Risks and Management. Curr Vasc Pharmacol. 2019;17(6):556-63. Doi: 10.2174/1570161116666180625124405.


15. Sun P., Wen H., Liu X., et al. Time trends in type 2 diabetes mellitus incidence across the BRICS from 1990 to 2019: an age-period-cohort analysis. BMC Public Health. 2022;22(1):65. Doi: 10.1186/s12889-021-12485-y.


16. Ren Y., Zhang M., Liu Y., et al. Association of menopause and type 2 diabetes mellitus. Menopause. 2019;26(3):325-330. Doi: 10.1097/GME.0000000000001200.


17. Brand J.S., van der Schouw Y.T., Onland-Moret N.C., et al. Age at menopause, reproductive life span, and type 2 diabetes risk: results from the EPIC-InterAct study. Diabetes Care. 2013;36(4):1012-19. Doi: 10.2337/dc12- 1020.


18. Muka T., Asllanaj E., Avazverdi N., et al. Age at natural menopause and risk of type 2 diabetes: a prospective cohort study. Diabetologia. 2017;60(10):1951-60. Doi: 10.1007/s00125- 017-4346-8.


19. Anagnostis P., Christou K., Artzouchaltzi A.M., et al. Early menopause and premature ovarian insufficiency are associated with increased risk of type 2 diabetes: a systematic review and metaanalysis. Eur J Endocrinol. 2019;180(1):41-50. Doi: 10.1530/EJE-18-0602.


20. Janssen I., Powell L.H., Crawford S., et al. Menopause and the metabolic syndrome: the Study of Women’s Health Across the Nation. Arch Intern Med. 2008;168(14):1568-75. Doi: 10.1001/archinte.168.14.1568.


21. Koistinen H.A., Zierath J.R. Regulation of glucose transport in human skeletal muscle. Ann Med. 2002;34(6):410-8. Doi: 10.1080/078538902321012351.


22. Barros R.P, Gustafsson J.A. Estrogen receptors and the metabolic network. Cell Metab. 2011;14(3):289-99. Doi: 10.1016/j. cmet.2011.08.005.


23. Geraci A, Calvani R, Ferri E, et al. Sarcopenia and Menopause: The Role of Estradiol. Front Endocrinol (Lausanne). 2021;12:682012. Doi: 10.3389/fendo.2021.682012.


24. Clegg D.J., Brown L.M., Woods S.C., et al. Gonadal hormones determine sensitivity to central leptin and insulin. Diabetes. 2006;55(4):978-87. Doi: 10.2337/diabetes.55.04.06.db05-1339. Erratum in: Diabetes. 2007 Oct;56(10):2649.


25. Wohlers L.M., Spangenburg E.E. 17beta-estradiol supplementation attenuates ovariectomy-induced increases in ATGL signaling and reduced perilipin expression in visceral adipose tissue. J Cell Biochem. 2010;110(2):420-27. Doi: 10.1002/ jcb.22553.


26. Zhao J, Wu Y, Rong X, et al. Anti-Lipolysis Induced by Insulin in Diverse Pathophysiologic Conditions of Adipose Tissue. Diabetes Metab Syndr Obes. 2020;13:1575-85. Doi:10.2147/DMSO.S250699.


27. Yan H., Yang W., Zhou F., et al. Estrogen Improves Insulin Sensitivity and Suppresses Gluconeogenesis via the Transcription Factor Foxo1. Diabetes. 2019;68(2):291-304. Doi:10.2337/db18- 0638.


28. Jones M., Tett S., Peeters G.M., et al. New-Onset Diabetes After Statin Exposure in Elderly Women: The Australian Longitudinal Study on Women’s Health. Drugs Aging. 2017;34(3):203-9. Doi: 10.1007/s40266-017-0435-0.


29. Nazarzadeh M., Bidel Z., Canoy D., et al. Blood pressure lowering and risk of new-onset type 2 diabetes: an individual participant data metaanalysis. Lancet.2021:398(10313):1803-10. Doi: 10.1016/S0140-6736(21)01920-6.


30. Baber R.J., Panay N., Fenton A. IMS Writing Group. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016;19(2):109-50. Doi: 10.3109/13697137.2015.1129166.


31. Manson JE, Rimm EB, Colditz GA, et al. A prospective study of postmenopausal estrogen therapy and subsequent incidence of non-insulindependent diabetes mellitus. Ann Epidemiol. 1992;2(5):665-73. Doi: 10.1016/1047- 2797(92)90011-e.


32. Kapoor E., Kling J.M., Lobo A.S., et al. Menopausal hormone therapy in women with medical conditions. Best Pract Res Clin Endocrinol Metab. 20215(6):101578. Doi: 10.1016/j. beem.2021.101578.


33. Kanaya A.M., Herrington D., Vittinghoff E., et al. Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study. A randomized, doubleblind, placebo-controlled trial. Ann Intern Med. 2003;138(1):1-9. Doi: 10.732 6/0003-4819-138-1-200301070-00005.


34. Margolis K.L., Bonds D.E., Rodabough R.J., et al. Women’s Health Initiative Investigators. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women’s Health Initiative Hormone Trial. Diabetologia. 2004;47(7):1175-87. Doi: 10.1007/s00125-004-1448-x.


35. Manson J.E., Kaunitz A.M. Menopause Management-Getting Clinical Care Back on Track. N Engl J Med. 2016;374(9):803-6. Doi: 10.1056/NEJMp1514242.


36. Salpeter S.R., Walsh J.M., Ormiston T.M., et al. Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes Metab. 2006;8(5):538-54. Doi:10.1111/ j.1463-1326.2005.00545.x.


37. de Lauzon-Guillain B., Fournier A., Fabre A., et al. Menopausal hormone therapy and new-onset diabetes in the French Etude Epidemiologique de Femmes de la Mutuelle Gene rale de l’Education Nationale (E3N) cohort. Diabetologia. 2009;52(10):2092-100. Doi: 10.1007/ s00125-009-1456-y.


38. Rizzo M.R., Leo S., De Franciscis P., et al. Shortterm effects of low-dose estrogen/drospirenone vs low-dose estrogen/dydrogesterone on glycemic fluctuations in postmenopausal women with metabolic syndrome. Age (Dordr). 2014;36(1):265-74. Doi: 10.1007/s11357- 013-9554-7.


39. Vujovic S., Ivovic M., Tancic-Gajic M., et al. Effects of different menopause hormone therapy routes of administration on insulin levels in early menopausal non-diabetic subjects. Gyn Rep End Met. 2021;2(1):60-4.


40. Papadakis G.E., Hans D., Gonzalez Rodriguez E., et al. Menopausal Hormone Therapy Is Associated With Reduced Total and Visceral Adiposity: The OsteoLaus Cohort. J Clin Endocrinol Metab. 2018;103 (5): 1948-.57. Doi: 10.1210/ jc.2017-02449.


41. Kim S.W., Kim R. The association between hormone therapy and sarcopenia in postmenopausal women: the Korea National Health and Nutrition Examination Survey, 20082011. Menopause. 2020;27(5):506-11. Doi: 10.1097/GME.0000000000001509.


42. Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of breast cancer: nested case-control studies using the QResearch and CPRD databases. BMJ. 2020;371:m3873.


43. Garda-Estevez L., Cortes J., Perez S., et al. Obesity and Breast Cancer: A Paradoxical and Controversial Relationship Influenced by Menopausal Status. Front Oncol. 2021;11:705911. Doi: 10.3389/ fonc.2021.705911.


44. Boyle P., Boniol M., Koechlin A., et al. Diabetes and breast cancer risk: a meta-analysis. Br J Cancer. 20123;107(9):1608-17. Doi: 10.1038/ bjc.2012.414.


45. Hou N., Hong S., Wang W., et al Hormone replacement therapy and breast cancer: heterogeneous risks by race, weight, and breast density. J Natl Cancer Inst. 2013 Sep 18;105(18):1365-72. Doi: 10.1093/jnci/ djt207.


46. Suba Z. Circulatory estrogen level protects against breast cancer in obese women. Recent Pat Anticancer Drug Discov. 2013;8(2):154-67. Doi: 10.2174/1574892811308020004


47. Renoux C, Dell’Aniello S, Suissa S. Hormone replacement therapy and the risk of venous thromboembolism: a population-based study. J Thromb Haemost. 2010 May;8(5):979- 86. Doi: 10.1111/j.1538-7836.2010. 03839.x.


48. Hotoleanu C. Association between obesity and venous thromboembolism. Med Pharm Rep. 2020;93(2):162-68. Doi:10.15386/mpr-1372.


49. Charlier S.H.R., Meier C., Jick, S.S. et al. Association between glycemic control and risk of venous thromboembolism in diabetic patients: a nested case-control study. Cardiovasc Diabetol. 2022;21(2). Doi.org/10.1186/s12933-021- 01432-1.


50. Canonico M., Oger E., Plu-Bureau G., et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007;115(7):840-45. Doi: 10.1161/ CIRCULATIONAHA.106.642280.


Об авторах / Для корреспонденции


Автор для связи: Сергей Сергеевич Апетов, к.м.н, врач-эндокринолог, акушер-гинеколог, ООО «Центр эндокринного здоровья», Челябинск, Россия; apetov@rambler.ru, https://orcid.org/0000-0001-8053-8561


Похожие статьи


Бионика Медиа